Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:33 PM
Ignite Modification Date:
2025-12-24 @ 12:33 PM
NCT ID:
NCT00010361
Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
* Inherited disorders treatable with allogeneic peripheral blood or bone marrow transplantation At high risk for regimen related toxicity with a conventional transplant
* No severe CNS involvement of disease, defined by IQ score less than 70
* HLA matched donor Sibling donors must be a confirmed match at HLA-A, B, and DRB1 Other related and non-related donors must be matched at HLA-A, B, C, DRB1, and DQB1 A donor homozygous for one allele only at HLA-A, B, C, DRB1, or DQB1 allowed (1 antigen mismatch for graft-versus-host disease, 0 antigen mismatch for graft-rejection)
--Prior/Concurrent Therapy--
* No concurrent growth factors with mycophenolate mofetil
--Patient Characteristics--
* Age: Under 55
* Performance status: Not specified
* Life expectancy: At least 100 days
* Hematopoietic: Not specified
* Hepatic: No evidence of synthetic dysfunction No severe cirrhosis
* Renal: Not specified
* Cardiovascular: LVEF at least 30% No poorly controlled hypertension on multiple antihypertensives
* Other: No organ dysfunction that would preclude survival Not pregnant or nursing Fertile patients must use effective contraception during and for 12 months following study
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
55 Years
Study:
NCT00010361
Study Brief:
Protocol Section:
NCT00010361